SG Biomedical focuses on expanding its presence in the Asian market across two key sectors: Medical Cold Plasma and Medical Intelligence.
In the field of Medical Cold Plasma, the company leverages innovative medical-grade cold plasma technology to treat a range of conditions—including acute and chronic large-scale wounds, chronic diabetic foot ulcers, surgical site infections, and infected burns. The significant therapeutic efficacy of this technology has been validated in over 82 professional medical journals worldwide. SG Biomedical is currently pursuing regulatory certifications and commercial expansion across Taiwan, six Southeast Asian nations, and other major Asian markets. As of June 2025, the company has formed a strategic equity alliance with a major U.S. biotechnology fund—a partnership spanning Taiwan, the U.K., the U.S., and Japan. Furthermore, the company has initiated the process for U.S. FDA certification while deepening its market penetration in Europe and Asia, all as part of a comprehensive strategy to establish a leading global commercial footprint in plasma medicine.
In the realm of Medical Intelligence, SG Biomedical is collaborating with major domestic medical institutions to develop Taiwan's first "Sovereign AI Large Language Model" for the healthcare sector. This initiative prioritizes data localization, model autonomy, and on-premises compliance. As the global digital landscape evolves rapidly, nations and specific industries are placing increasing emphasis on information security, geopolitics, and cultural localization. In healthcare—where medical records, genetic data, and clinical expertise constitute highly sensitive, core national assets—"Sovereign AI" has emerged as a pivotal market trend. SG Biomedical has established this specialized language model, using Taiwan's medical institutions as a foundational demonstration site, with plans for a phased rollout across the broader Asia-Pacific healthcare market.


In light of the long-term growth trends within the healthcare market, SG Biomedical remains committed to deepening the integration of its "Medical Cold Plasma" with "Medical Intelligence" applications. By combining cross-disciplinary technologies with established medical distribution channels, we aim to expand the use cases for our products and services, striving to deliver high-value healthcare solutions for the broader health and wellness industry.
Guided by our core values of integrity and honesty, we remain steadfast in upholding our commitments to our clients, suppliers, employees, shareholders, and society at large. As we look toward the vast potential of the biotechnology and healthcare sector, SG Biomedical—fueled by deep passion and a firm dedication to the industry—looks forward to working alongside our employees to forge a future of limitless possibilities.